CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [**], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO IRONWOOD PHARMACEUTICALS, INC. IF PUBLICLY DISCLOSED.Collaboration Agreement • September 18th, 2019 • Ironwood Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED COLLABORATION AGREEMENT, entered into this 16th day of September, 2019 (the “Amendment Date”) by and between Ironwood Pharmaceuticals, Inc., a corporation organized under the laws of Delaware (“Ironwood”) and AstraZeneca AB, a corporation organized under the laws of Sweden (“AstraZeneca”), hereby amends and restates that certain Collaboration Agreement (the “Prior Agreement”, and as amended by this amendment, the “Agreement”) entered into by and between Ironwood and AstraZeneca on the 23rd day of October, 2012 (the “Effective Date”). Ironwood and AstraZeneca may be referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
